Trial Profile
Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Omaveloxolone (Primary)
- Indications Malignant melanoma
- Focus Expanded access; Therapeutic Use
- Sponsors Reata Pharmaceuticals
- 28 Aug 2020 Status changed from recruiting to completed.
- 26 Jul 2018 New trial record